Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | IO-108 |
Trade Name | |
Synonyms | IO 108|IO108 |
Drug Descriptions |
IO-108 is an antibody that targets LILRB2/ILT4 and.prevents ligand interaction, potentially resulting in increased antitumor immune response (Journal for ImmunoTherapy of Cancer 2020;8). |
DrugClasses | LILRB2 Antibody 11 |
CAS Registry Number | NA |
NCIT ID | C185720 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
IO-108 | IO-108 | 0 | 1 |
IO-108 + Pembrolizumab | IO-108 Pembrolizumab | 0 | 1 |